| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5697916 | Clinical Oncology | 2016 | 9 Pages |
Abstract
One-third of NSCLC patients did not receive GRT. Stage and performance status were key predictors for GRT receipt. Patients with early stage NSCLC were associated with improved survival with the receipt of GRT.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
K.J. Duggan, J. Descallar, S.K. Vinod,